Net income was $1.0 million, or $0.24 per diluted share, for the quarter ended March 31, 2026, compared to $1.7 million, or $0.41 per diluted share, for the comparable period last year, a decrease of 40% in net income and 41% diluted earnings per share. This decrease was due to higher cost of sales and increased operating expenses primarily as a result of higher tariff-related costs and investments in enhanced quality assurance protocols at the Med-Nap facility, together with rising employee healthcare expenses. Tariff expenses were recognized during the first quarter as the company sold inventory that had been subject to higher tariff rates imposed in 2025.